<?xml version="1.0" encoding="UTF-8"?>
<p>IL-6 inhibitors, such as Tocilizumab, are currently being tried as a potential treatment for COVID-19 patients to reduce inflammation in the lungs and prevent progressive damage [
 <xref rid="B132-antioxidants-09-00636" ref-type="bibr">132</xref>]. Results thus far have shown benefit in the treatment group versus the standard of care and are currently in phase III clinical trials as of April 15th. There are reports of Gram-negative sepsis with the use of this drug [
 <xref rid="B133-antioxidants-09-00636" ref-type="bibr">133</xref>]. Tocilizumab has the potential to affect the expression of several CYP enzyme polymorphisms including CYP3A4 and CYP2D6 [
 <xref rid="B134-antioxidants-09-00636" ref-type="bibr">134</xref>].
</p>
